Bispecific antibody treatment of multiple myeloma: latest updates from the 2022 ASH annual meeting
Background: Effective novel therapies for multiple myeloma (MM) patients who are unresponsive to conventional treatments (triple-class refractory) are an urgent need. Bispecific antibodies (BsAbs) offer a promising new approach to stimulate T cells and induce tumor cell death by targeting molecules...
Gorde:
| Egile Nagusiak: | , , , , , |
|---|---|
| Formatua: | Liburua |
| Argitaratua: |
SAGE Publishing,
2023-11-01T00:00:00Z.
|
| Gaiak: | |
| Sarrera elektronikoa: | Connect to this object online. |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|